Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma.
Robert E SchoenLisa A BoardmanMarcia Roxana Cruz-CorreaAjay BansalDavid M KastenbergChin HurLynda Ann DzubinskiSharon F KaufmanLuz Maria RodriguezEllen RichmondAsad UmarEva SzaboAndres SalazarJohn McKolanisPamela L BeattyReetesh K PaiAatur D SinghiCamille M JacquelineRiyue BaoBrenda DiergaardeRyan P McMurrayCarrie A StrandNathan R FosterDavid M ZahriehPaul J LimburgOlivera J FinnPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
An immune response was observed only in vaccine recipients. Adenoma recurrence was not different than placebo, but a 38% absolute reduction in adenoma recurrence compared to placebo was observed in participants who had an immune response at week 12 and with the booster injection.